{"id":11153,"date":"2026-11-06T18:06:03","date_gmt":"2026-11-06T12:36:03","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-11-06\/"},"modified":"2026-11-06T18:06:05","modified_gmt":"2026-11-06T12:36:05","slug":"glenmark-share-price-today-2026-11-06","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-11-06\/","title":{"rendered":"Glenmark Pharmaceuticals Share Price Jumps 8.06% Intraday, Closes 4.36% Higher | 6 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: GLENMARK<\/strong> \u00b7 6 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,590.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+4.36%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,682.50 \/ \u20b92,365.50<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,481.80<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>50.37 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>6 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Glenmark Pharmaceuticals shares moved higher on Thursday, gaining 4.36% to trade at \u20b92,590.00. The stock opened at \u20b92,399.00 and ranged between an intraday low of \u20b92,365.50 and a high of \u20b92,682.50, which also marks its 52-week peak.<\/li>\n<li>Glenmark Pharmaceuticals reported consolidated revenue of \u20b942,473 million for the quarter ended September 30, 2026, marking a like-for-like year-on-year growth of approximately 20%. The company posted an EBITDA of \u20b98,638 million with an EBITDA margin of 20.3% and an adjusted PAT of \u20b94,852 million. Key regional drivers included a like-for-like growth of ~14% in the India business, ~31% core growth in North America, 6.2% growth in Europe, and 33.2% growth across Emerging Markets.<\/li>\n<li>Trading volume was 7.98 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Glenmark Pharmaceuticals share price rising on 6 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals shares moved higher on Thursday, gaining 4.36% to trade at \u20b92,590.00. The stock opened at \u20b92,399.00 and ranged between an intraday low of \u20b92,365.50 and a high of \u20b92,682.50, which also marks its 52-week peak.<\/p>\n<p class=\"wt-copy\">The broader market and sectoral benchmarks showed positive momentum on Thursday, with the Nifty advancing 2.01% and the Nifty Pharma sector index gaining 1.21%. Glenmark&#x27;s performance outpaced both indices. The stock has demonstrated strong recent momentum, posting a 5-day return of 12.67% and a 20-day return of 18.15%, reflecting sustained buying interest across the pharmaceutical sector.<\/p>\n<p class=\"wt-copy\">While the broader rally provided supportive tailwinds, market participants have also been processing the company&#x27;s recent operational updates and financial results for the quarter ended September 30, 2026, reported earlier in the week. Glenmark posted a consolidated revenue of \u20b942,473 million, with a like-for-like year-on-year growth of approximately 20%, alongside an EBITDA of \u20b98,638 million and an adjusted PAT of \u20b94,852 million. Additionally, the company announced that Ichnos Glenmark Innovation&#x27;s Phase 1 data for ISB 2001 has been selected for an oral presentation at the upcoming 68th American Society of Hematology Annual Meeting.<\/p>\n<p class=\"wt-copy\">50.37 lakh shares traded by 6 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 6.31 lakh shares (7.98 times). The five-day average daily volume was 9.06 lakh shares. Separately, the NSE report for 6 November 2026 showed 10.64 lakh shares delivered, representing 21.12% of that day\u2019s traded volume. The same report recorded 195,570 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Post-earnings follow-through and sector outperformance<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s advance appears supported by follow-through buying following its recent Q2 earnings release, combined with broader outperformance across pharmaceutical equities and elevated cash-market volume.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2 FY27 Financial Results &amp; Business Update<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals reported consolidated revenue of \u20b942,473 million for the quarter ended September 30, 2026, marking a like-for-like year-on-year growth of approximately 20%. The company posted an EBITDA of \u20b98,638 million with an EBITDA margin of 20.3% and an adjusted PAT of \u20b94,852 million. Key regional drivers included a like-for-like growth of ~14% in the India business, ~31% core growth in North America, 6.2% growth in Europe, and 33.2% growth across Emerging Markets.<\/p>\n<p class=\"wt-copy\">Provides a comprehensive view of operational profitability and core market execution across international regions.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Clinical Data Presentation for ISB 2001 at ASH Annual Meeting<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Ichnos Glenmark Innovation announced that updated clinical data from the Phase 1 TRIgnite-1 study of ISB 2001 in relapsed\/refractory multiple myeloma has been selected for an oral presentation at the 68th American Society of Hematology Annual Meeting. The data features longer follow-up from dose-escalation cohorts and early results from dose-expansion cohorts in heavily pretreated patients.<\/p>\n<p class=\"wt-copy\">Highlights clinical advancement and commercial visibility for the company&#x27;s partnered oncology pipeline.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">U.S. FDA Establishment Inspection Report for Goa Facility<\/div>\n<div class=\"wt-card-date\">23 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals received the Establishment Inspection Report from the U.S. FDA for its Goa manufacturing facility, with a Voluntary Action Indicated classification following a prior inspection. This follows other regulatory milestones, including an EIR with VAI classification for the Monroe facility.<\/p>\n<p class=\"wt-copy\">Reinforces manufacturing compliance and supports regulatory clearance for export pipelines into key developed markets.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_23092026083959_SEPressRelease23092026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated November 05, 2026, titled &quot;Press Release for Q2 FY&#x27;27&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_05112026171553_PR_MDA_05112026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_05112026170258_SEInitmationresults.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">46.65%<\/div>\n<div class=\"wt-note\">46.65% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">21.51%<\/div>\n<div class=\"wt-note\">20.89% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">39.15%<\/div>\n<div class=\"wt-note\">39.49% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741223_19102026122950_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 15.61% on 30 September 2026. This compares with 16.76% on 30 June 2026, a change of -1.15 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 38 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND &#8211; HDFC MANUFACTURING FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.70 crore shares \u00b7 6.01%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">INVESCO INDIA PHARMA AND HEALTHCARE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">55.73 lakh shares \u00b7 1.97%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">BANDHAN LARGE CAP FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">36.18 lakh shares \u00b7 1.28%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741223_19102026122950_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b92,570.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Included Glenmark Pharma among top stock picks highlighting technical and fundamental momentum.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI Securities<\/div>\n<div class=\"wt-card-date\">4 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Hold<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b92,100.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a hold rating with a target price of Rs 2100 following previous earnings assessments.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of North American product launches and regulatory progress on pending ANDAs<\/li>\n<li>Clinical update presentations for ISB 2001 at the upcoming ASH Annual Meeting<\/li>\n<li>Sustained delivery volume participation above the 20-day average of ~7.98x<\/li>\n<li>Performance trends across core therapy franchises in domestic and emerging markets<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-23\/\">Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 3.55% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-08\/\">Glenmark Pharmaceuticals in Focus After US Adapalene Gel Launch | 8 October 2026 \u2014 8 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-10-07\/\">Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 1.24% | 7 October 2026 \u2014 7 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/glenmark\/\">More Glenmark Pharmaceuticals news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Glenmark Pharmaceuticals company news?<\/h3>\n<p class=\"wt-copy\">Glenmark Pharmaceuticals reported consolidated revenue of \u20b942,473 million for the quarter ended September 30, 2026, marking a like-for-like year-on-year growth of approximately 20%. The company posted an EBITDA of \u20b98,638 million with an EBITDA margin of 20.3% and an adjusted PAT of \u20b94,852 million. Key regional drivers included a like-for-like growth of ~14% in the India business, ~31% core growth in North America, 6.2% growth in Europe, and 33.2% growth across Emerging Markets.<\/p>\n<h3>How strong was Glenmark Pharmaceuticals\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">50.37 lakh shares traded, 7.98 times the 20-day average daily volume. The price and volume data are dated 6 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-11-06\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/glenmark-share-price-today-2026-11-06\/\"}, \"headline\": \"Glenmark Pharmaceuticals Share Price Jumps 8.06% Intraday, Closes 4.36% Higher | 6 November 2026\", \"description\": \"Glenmark Pharmaceuticals moved 8.06% intraday and closed 4.36% higher at \u20b92,590.00. See the catalyst, volume context and what to watch next.\", \"datePublished\": \"2026-11-06T18:05:51.990059+05:30\", \"dateModified\": \"2026-11-06T18:05:51.990059+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Glenmark Pharmaceuticals\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"GLENMARK\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/glenmark-company-news-2026-11-06.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Updates\",\"summary\":\"'Investors Presentation'.\",\"source\":\"NSE\",\"published\":\"05-Nov-2026 17:24:34\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_05112026172410_SEInvestorPresentation.pdf\",\"disclosure_text\":\"Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B\/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com November 05, 2026 To, National Stock Exchange of India Limited, \u201cExchange Plaza\u201d, 5th Floor, Plot No. C\/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai \u2013 400 051 To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 66\/26-27 Our Reference No. 66\/26-27 Dear Sir\/ Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation \u2013 Q2 FY 26-27. You are requested to take the same on record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS \u2013 28839 Encl: As above Investor Presentation Q2 FY27 05 November 2026 Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company\u2019s or its affiliates\u2019 objectives, projections and estimates are forward looking statements. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as \u201canticipates\u201d, \u201cbelieves\u201d, \u201cestimates\u201d, \u201cexpects\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cpredicts\u201d, \u201cprojects\u201d, \u201caspirations\u201d, \u201cgoals\u201d, \u201caim\u201d, \u201ctargets\u201d, \u201cpromises\u201d and similar expressions. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements, depending upon, without limitation: \u2022 General economic and political conditions in our key markets, government policies and other incidental factors; \u2022 Changes in the overall macro-economic parameters including changes in the currency and interest rates either in India and \/ or globally; \u2022 Ability to successfully implement our strategic plan, including research and development efforts; \u2022 Changes in laws and regulations that apply to the pharmaceutical industry and its suppliers and customers; and \u2022 Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry Actual outcomes may vary materially from those indicated in the applicable forward-looking statements, should one or more of such risks and uncertainties materialize. No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment. The Company undertakes no obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise. Certain information in this document is not audited or reviewed by an auditor or based on Indian Accounting Standards or internationally accepted accounting principles. The reader should not consider such items as an alternative to the audited financial results or other indicators of the Company\u2019s profit, cash flows or financial performance based on applicable accounting standards. This presentation is property of Glenmark Pharmaceuticals Ltd. Do not alter in any way or reproduce without permission. 2 Summary \u2013 Q2 FY27 Consolidated Revenue \u2022 Consolidated Revenue of Rs. 42,473 million \u2022 Like-for-Like YoY growth of ~20% Regional Highlights \u2022 India 1 business growth of ~14% \u2022 North America 2 core business growth of ~31% \u2022 EU business growth of 6.2% \u2022 EM business growth of 33.2% Profitability \u2022 Consolidated R&D at Rs. 3,449 million \u2022 EBITDA at Rs. 8,638 million \u2022 EBITDA margin of 20.3% \u2022 Adj. PAT 3 at Rs. 4,852 million \u2022 Adj. PAT margin of 11.4% Glenn Saldanha Chairman and Managing Director Glenmark Pharmaceuticals Ltd. \u201cQ2 demonstrated the strength and resilience of Glenmark\u2019s base business. We remain on track to deliver our FY27 guidance with continued growth in India, a strong recovery in North America supported by multiple launches, and robust performance across Emerging Markets. RYALTRIS \u00ae continues to expand internationally with the recent Brazil launch marking an important milestone. Our partnered innovative oncology pipeline is advancing toward commercialization with the first launch expected by the end of FY27. IGI continues to advance its multispecific oncology pipeline with Phase 1 ISB 2001 data selected for oral presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. We also intend to submit an IND application for ISB 2301 by the end of this year. Together, these milestones underscore the strength of our innovation platform and position Glenmark for its next phase of sustainable, innovation-led growth and long-term value creation.\u201d 3 1. On a like-for-like basis, India formulation business recorded YoY growth of ~14% for Q2 FY27. 2. North America revenue for Q2 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY growth for the North America region was ~31% in Q2 FY27. 3. Adjusting for exceptional items as published in the consolidated results. Consolidated Revenue \u2013 Q2 FY27 Average conversion rate in 6M FY 2026-27 considered as INR 95.05 \/ USD 1.00 Average conversion rate in 6M FY 2025-26 considered as INR 86.42 \/ USD 1.00 USD figures are only indicative 1. On a like-for-like basis, India formulation business recorded YoY growth of ~14% for Q2 FY27. 2. North America revenue for Q2 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY growth for the North America region was ~31% in Q2 FY27. # Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC) 4 India 1 13,274 1,651 704.2% 14,321 -7.3% North America 2 12,089 44,656 -72.9% 10,974 10.2% Europe 7,920 7,460 6.2% 7,472 6.0% Emerging Markets # 8,769 6,585 33.2% 7,304 20.1% Total 42,052 60,352 -30.3% 40,071 4.9% Other Revenue 421 117 261.0% 114 268.6% Consolidated Revenue 42,473 60,469 -29.8% 40,185 5.7% FY27 Second Quarter ended September 30 First Quarter ended June 30 Rs Mn FY27 FY26 YoY Growth QoQ Growth Consolidated Revenue \u2013 H1 FY27 Average conversion rate in 6M FY 2026-27 considered as INR 95.05 \/ USD 1.00 Average conversion rate in 6M FY 2025-26 considered as INR 86.42 \/ USD 1.00 USD figures are only indicative 1. On a like-for-like basis, India formulation business recorded YoY growth of ~15% for H1 FY27. 2. North America revenue for H1 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY growth for the North America region was ~25% in H1 FY27. # Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC) 5 India 1 27,595 14,050 96.4% North America 2 23,063 52,436 -56.0% Europe 15,392 14,138 8.9% Emerging Markets # 16,073 12,306 30.6% Total 82,122 92,930 -11.6% Other Revenue 536 183 192.7% Consolidated Revenue 82,658 93,113 -11.2% Six Months ended September 30 Rs Mn FY27 FY26 YoY Growth India Revenue (Rs. million)# 13,274 1,651 Q2 FY27 Q2 FY26 Sustained market-beating growth across core therapy franchises Expanded leadership positions in Respiratory and Dermatology Increasing strength of Oncology business; Glenmark advancing into Top 10 GCCL posted strong double-digit growth, led by market-leading brands 6 27,595 14,050 H1 FY27 H1 FY26 # On a like-for-like basis, India formulation business recorded YoY growth of ~14% for Q2 FY27 and ~15% for H1 FY27. North America Revenue (Rs. million)# 12,089 44,656 Q2 FY27 Q2 FY26 Launched 4 new products in Q2 FY27 Enhanced manufacturing and regulatory readiness with U.S. FDA EIRs for both Monroe and Goa facilities Fluticasone Nasal Spray [Rx] launched, working on additional Respiratory filings across MDIs and Nasal Sprays Launching additional products from Monroe in the upcoming quarters # North America revenue for Q2 and H1 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY growth was ~31% in Q2 FY27 and ~25% in H1 FY27 7 23,063 52,436 H1 FY27 H1 FY26 Europe Revenue (Rs. million) 7,920 7,460 Q2 FY27 Q2 FY26 YoY: 6.2% Delivered resilient performance despite uneven market conditions across the region Continued to strengthen the strategic portfolio through successful launches RYALTRIS\u00ae and WINLEVI\u00ae gained further traction across key markets Advancing long-term growth initiatives through launches, market access and scientific engagement 8 15,392 14,138 H1 FY27 H1 FY26 YoY: 8.9% Emerging Markets Revenue (Rs. million) 8,769 6,585 Q2 FY27 Q2 FY26 YoY: 33.2% Continued market outperformance, portfolio expansion, and strong execution across regions Ranked 6th among Dermatology companies in Russia LATAM: RYALTRIS\u00ae launched in Brazil MEA: Continued momentum, with RYALTRIS\u00ae gaining share across key markets APAC: Strong secondary sales growth driven by Dermatology and Respiratory 9 YoY: 30.6% 16,073 12,306 H1 FY27 H1 FY26\"},{\"title\":\"Press Release\",\"summary\":\"a press release dated November 05, 2026, titled \\\"Press Release for Q2 FY'27\\\".\",\"source\":\"NSE\",\"published\":\"05-Nov-2026 17:17:31\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_05112026171553_PR_MDA_05112026.pdf\",\"disclosure_text\":\"Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B\/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com November 05, 2026 To, National Stock Exchange of India Limited, \u201cExchange Plaza\u201d, 5th Floor, Plot No. C\/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai \u2013 400 051 To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 65\/26-27 Our Reference No. 65\/26-27 Dear Sir\/ Madam, Sub: Press Release and Management Discussion & Analysis Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the Press Release and Management Discussion & Analysis of the Company for the Second Quarter and Half Year ended September 30, 2026. You are requested to take the same on record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Encl: As above Glenmark Pharmaceuticals Announces Q2 FY27 Results Highlights \u2022 India Formulations revenue at Rs. 1 3,274 million; like-for-like growth of approximately 14% YoY \u2022 North America revenue of Rs. 12,089 million; Net of deferred out-licensing income recognition for ISB 2001, the core business grew approximately 31% YoY \u2022 Europe revenue of Rs. 7,920 million, growing 6.2% YoY \u2022 Emerging Markets revenue of Rs. 8,769 million, growing 33.2% YoY \u2022 EBITDA of Rs. 8,638 million, with an EBITDA margin of 20.3% \u2022 Adjusted Profit After Tax (PAT) of Rs. 4,852 million, with an adjusted PAT margin of 11.4% Mumbai, India, November 05, 2026: Glenmark Pharmaceuticals Ltd. (Glenmark), a research- led, global pharmaceutical company, today announced its financial results for the second quarter ended September 30, 2026. Consolidated revenue for Q2 FY27 was Rs. 42,473 million. On a like-for-like basis, consolidated revenue grew approximately 20% YoY. EBITDA for the quarter was Rs. 8,638 million, representing an EBITDA margin of 20.3%. Adjusted Profit After Tax (PAT) for the quarter was Rs. 4,852 million, with an adjusted PAT margin of 11.4%. Reported Profit After Tax (PAT) was Rs. 2,638 million, with a reported PAT margin of 6.2%. Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, \u201cQ2 demonstrated the strength and resilience of Glenmark\u2019s base business. We remain on track to deliver our FY27 guidance with continued growth in India, a strong recovery in North America supported by multiple lau nches, and robust performance across Emerging Markets. RYALTRIS\u00ae continues to expand internationally with the recent Brazil launch marking an important milestone. Our partnered innovative oncology pipeline is advancing toward commercialization with the first launch expected by the end of FY27. IGI continues to advance its multispecific oncology pipeline with Phase 1 ISB 2001 data selected for oral presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. We also intend to submit an IND application for ISB 2301 by the end of this year. Together, these milestones underscore the strength of our innovation platform and position Glenmark for its next phase of sustainable, innovation-led growth, and long-term value creation,\u201d he added. About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research\u2010led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world -class manufacturing facilities across four continents, supported by six cutting -edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health produc ts, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact: Akhila Natarajan | mediarelations@glenmarkpharma.com Adfactors PR | glenmark.ihcp@adfactorspr.com 1Management Discussion & Analysis: Q2 FY27 Management Discussion & Analysis for the Second Quarter of FY 2026-27 Revenue Figures \u2013 Consolidated (In Rs. million) For the second quarter ended September 30 For the six months ended September 30 FY27 FY26 Growth (%) FY27 FY26 Growth (%) India1 13,274 1,651 704.2% 27,595 14,050 96.4% North America2 12,089 44,656 -72.9% 23,063 52,436 -56.0% Europe 7,920 7,460 6.2% 15,392 14,138 8.9% Emerging Markets# 8,769 6,585 33.2% 16,073 12,306 30.6% Total 42,052 60,352 -30.3% 82,122 92,930 -11.6% Other Revenue 421 117 261.0% 536 183 192.7% Consolidated Revenue 42,473 60,469 -29.8% 82,658 93,113 -11.2% 1. On a like-for-like basis, India formulation business recorded YoY growth of ~14% for Q2 FY27 and ~15% for H1 FY27. 2. North America revenue for Q2 and H1 FY27 includes deferred out-licensing income recognition for ISB 2001; Net of this, the core business YoY growth for the North America region was ~31% in Q2 FY27 and ~25% in H1 FY27. # Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC) Average conversion rate in 6M FY 2026-27 considered as INR 95.05 \/ USD 1.00 Average conversion rate in 6M FY 2025-26 considered as INR 86.42 \/ USD 1.00 USD figures are only indicative Review of Operations for the Quarter ended September 30, 2026 For Q2 FY27, Glenmark\u2019s consolidated revenue from operations was at Rs. 42,473 million (USD 444.5 million) as against Rs. 60,469 million (USD 699.7 million) in the corresponding quarter last year. On a like-for-like basis, Glenmark\u2019s consolidated revenue in Q2 FY27 recorded YoY growth of ~20%. For H1 FY27, Glenmark\u2019s consolidated revenue from operations was Rs. 82,658 million (USD 869.6 million) as against Rs. 93,113 million (USD 1,081.3 million) in the corresponding quarter last year. On a like-for-like basis, Glenmark\u2019s consolidated revenue in H1 FY27 recorded YoY growth of ~18%. 2Management Discussion & Analysis: Q2 FY27 FORMULATION BUSINESS Glenmark\u2019s global formulations business is supported by a well-diversified mix of Branded, Generics, and OTC products, with leadership positions in Dermatology, Respiratory, and Oncology. INDIA Sales from the formulation business in India for Q2 FY27 was at Rs. 13,274 million (USD 138.8 million) as against Rs. 1,651 million (USD 19.1 million) in the corresponding quarter last year. On a like-for-like basis, India formulation business recorded YoY growth of ~14% in Q2 FY27 and ~15% in H1 FY27. Glenmark continued to significantly outperform the IPM in terms of secondary sales as per IQVIA. Glenmark\u2019s India formulation business recorded a growth of 16.7% in Q2 FY27 and 15.7% as per MAT SEP\u2019 2026, compared to IPM growth of 13.8% in Q2 FY27 and 12.1% in MAT SEP\u2019 2026. Glenmark continued to sustain strong growth in its core therapy areas like Dermatology, Respiratory, Cardiac and Oncology. VALUE GROWTH % (JUL\u201926 - SEP'26) VALUE GROWTH % (MAT SEP'26) SUPERGROUP IPM GLENMARK IPM GLENMARK CARDIAC 17.0 18.8 16.5 18.1 DERMATOLOGY 13.5 12.8 10.5 11.9 RESPIRATORY 4.6 9.6 9.1 11.2 DIABETES 17.7 -4.2 16.1 -3.9 Glenmark\u2019s India business is ranked 13 th with a market share of 2.4% as per IQVIA MAT SEP\u2019 2026. The Company has 11 brands in the IPM Top 300 Brands in the country as of IQVIA MAT SEP\u2019 2026. In terms of core therapy areas, Glenmark is ranked 2 nd in Dermatology, 3 rd in Respiratory and 4th in the Cardiac segment as per IQVIA MAT SEP\u2019 2026. Reflecting the growing strength of its Oncology franchise, Glenmark has advanced into the Top 10 companies in the Oncology market, improving its ranking by six positions year-on-year, according to the IPSOS MAT JUN\u2019 2026 dataset. SUPERGROUP GLENMARK MARKET SHARE % MAT SEP'25 GLENMARK MARKET SHARE % MAT SEP'26 CARDIAC 6.0 6.1 DERMATOLOGY 8.3 8.4 RESPIRATORY 5.9 6.0 DIABETES 1.2 1.0 3Management Discussion & Analysis: Q2 FY27 TEVIMBRA\u00ae (TISLELIZUMAB) & BRUKINSA\u00ae (ZANUBRUTINIB) PARTNERED WITH BEONE \uf0b7 Glenmark launched Tislelizumab and Zanubrutinib in India under the respective brand names TEVIMBRA\u00ae and BRUKINSA\u00ae in Q1 FY26. \uf0b7 TEVIMBRA \u00ae (Tislelizumab) and BRUKINSA \u00ae (Zanubrutinib) continued to build strong momentum in the Indian Oncology market, reinforcing Glenmark's strategic focus on bringing innovative therapies to patients. \uf0b7 On the back of these two launches, Glenmark has further strengthened its standing in Oncology and is now ranked 4th among Indian pharmaceutical companies in Oncology. NEBZMART\u00ae GFB Smartules\u00ae \/ GLENMARK AIRZ\u00ae FB Smartules\u00ae \uf0b7 In Q3 FY26, Glenmark announced the launch of NEBZMART \u00ae GFB Smartules \u00ae and Glenmark AIRZ\u00ae FB Smartules\u00ae, the world\u2019s first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD) \uf0b7 Both products combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. As a single, easy-to-use nebulized therapy, it minimizes the burden of multiple medications. \uf0b7 NEBZMART \u00ae GFB Smartules\u00ae and GLENMARK AIRZ\u00ae FB Smartules\u00ae have demonstrated strong market traction since launch, further enhancing Glenmark's leadership position in Respiratory care and drug-device innovation. JABRYUS\u00ae PARTNERED WITH PFIZER \uf0b7 Glenmark launched JABRYUS \u00ae (Abrocitinib), a first of its kind oral advanced systemic treatment for the treatment of moderate-to-severe Atopic Dermatitis (AD) in India in partnership with Pfizer. \uf0b7 JABRYUS \u00ae has been well received by dermatologists as a novel treatment for moderate-to- severe AD, with improved efficacy and oral convenience to patients. INDIA \u2013 GLENMARK CONSUMER CARE LIMITED (GCCL) Primary sales for GCCL in Q2 FY27 were Rs. 1,252 million with a YoY growth of 46.5%. GCCL delivered a strong performance in Q2 FY27, driven by sustained momentum across its key brands. \uf0b7 CANDID POWDER\u2122, the flagship brand, reported >40% growth during the quarter and further strengthened its leadership position in the category. It expanded its market leadership, reaching ~60% market share, as per the IQVIA SEP\u2019 2026 dataset. \uf0b7 LA SHIELD\u2122 portfolio delivered robust growth of ~35% in Q2 FY27 across its key variants. \uf0b7 The SCALPE\u2122 portfolio continued its strong growth trajectory, registering ~70% growth during the quarter, supported by healthy performance across key variants. \uf0b7 Other brands such as BONTRESS\u2122 and EPISOFT\u2122 delivered impressive growth. 4Management Discussion & Analysis: Q2 FY27 These results reflect the continued strength of GCCL's core brands and successful execution of its growth strategy across the derma-cosmetic segment. NORTH AMERICA North America recorded revenue of Rs. 12,089 million (USD 126.6 million) for Q2 FY27 as against revenue of Rs. 44,656 million (USD 516.7 million) for Q2 FY26. Net of the deferred out-licensing income recognition for ISB 2001, the core business YoY growth for the North America region was ~31% in Q2 FY27 and ~25% in H1 FY27. During the quarter, Glenmark launched a total of four products across multiple channels; notable launches included Sugammadex Injection, Fluticasone Nasal Spray USP (Rx) and Nintedanib Capsules. In addition to these product launches, Glenmark also launched additional pack sizes for multiple existing products. Glenmark is looking towards beginning distribution of several new in- licensed products in Q3 FY27. Glenmark has strengthened its generic Respiratory franchise with its first ANDA approval, Fluticasone Propionate Inhalation Aerosol USP, 44 mcg (generic to FloVent \u00ae HFA Inhalation Aerosol, 44 mcg). Glenmark was granted a Competitive Generic Therapy (CGT) designation for this product as the first approved applicant and received 180 days of exclusivity upon commercialization. Glenmark also received approval for Fluticasone Propionate Nasal Spray USP, both Rx and OTC formulations. Glenmark has also initiated end-to-end commercialization and will directly lead brand strategy, market access, and customer engagement for RYALTRIS\u00ae in the USA. Glenmark has filed additional ANDAs for differentiated Respiratory products, including the ANDA for Fluticasone Propionate Inhalation Aerosol USP, 110 mcg (generic to FloVent\u00ae HFA Inhalation Aerosol, 110 mcg) and for Ipratropium Bromide Inhalation Aerosol (generic to ATROVENT \u00ae HFA). The Company is working on additional Respiratory filings across MDIs and Nasal Sprays. Glenmark has built a large portfolio of 20 commercial injectable products through various partners. Glenmark\u2019s injectable manufacturing facility in Monroe, North Carolina received the EIR from U.S. FDA with a VAI classification in November 2025 and re-launched Fulvestrant Injection out of the Monroe facility in Q1 FY27. The company is working on launching additional products from Monroe in the upcoming quarters. During the second quarter, the Company\u2019s Goa manufacturing facility received Establishment Inspection Report (EIR) from the U.S. FDA with a VAI classification. Glenmark\u2019s marketing portfolio through September 30, 2026, consists of 229 generic products 1 authorized for distribution in the U.S. market. The Company currently has 51 applications pending in various stages of the approval process with the US FDA, of which 25 are Paragraph IV applications. 5Management Discussion & Analysis: Q2 FY27 Litigation Update As previously disclosed, there were multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S. against the Company\u2019s subsidiary Glenmark Pharmaceuticals Inc., USA, (\u201cGlenmark USA\u201d) in connection with allegations of price-fixing, market allocation, and related anti-competitive conduct. The plaintiffs include classes of direct purchasers, endpayers, and indirect purchasers of generic drugs, as well as numerous private, direct-action plaintiffs, and 46 state attorneys general. Three complaints filed by Humana, Inc. (\u201cHumana\u201d) were included in the consolidated litigation. With a view to resolve this dispute and avoiding uncertainty, Glenmark USA has agreed to enter into a settlement with Humana for the total amount of $15.28 million ($15,285,369), including interest, payable in two installments. The settlement makes clear that Glenmark USA denies each and every one of the allegations made against it and the settlement does not constitute any concession or admission of liability, wrongdoing, or illegality on the part of Glenmark USA. The full amount of payments under the settlement agreements have been provided for in the Company\u2019s financials. 1All marketed products and any products authorized for distribution where Glenmark is the ANDA holder. Note: All brand names and trademarks are property of their respective owners. IQVIA National Sales Perspectives: Retail and Non-Retail, August 2026. EUROPE Glenmark Europe operations\u2019 revenue for Q2 FY27 was Rs. 7,920 million (USD 82.9 million) as against Rs. 7,460 million (USD 86.3 million) recording a growth of 6.2%. Europe delivered a mixed performance during the quarter, with strong momentum across several Western European markets partly offset by softer demand in parts of Central and Eastern Europe. The region continued to strengthen its strategic portfolio through successful launches and commercialization of key brands, particularly RYALTRIS \u00ae and WINLEVI \u00ae, which gained further market acceptance across multiple countries. Strong execution in Respiratory and Dermatology specialty portfolios, supported by favorable tender outcomes, market access initiatives and customer engagement programs, helped sustain business momentum. The quarter also saw continued investment in medical education, scientific congresses, physician outreach and digital engagement activities, reinforcing the region's commercial presence and supporting long-term brand development. Europe remains focused on accelerating growth through its differentiated Respiratory, Dermatology and specialty portfolios. Continued momentum from strategic brands such as RYALTRIS \u00ae and WINLEVI\u00ae, together with a robust launch pipeline and enhanced market access initiatives, positions the region well for sustainable long-term growth. 6Management Discussion & Analysis: Q2 FY27 EMERGING MARKETS (RCIS, LATAM, MEA & APAC) For Q2 FY27, revenue from the EM region was Rs. 8,769 million (USD 91.9 million) as against Rs. 6,585 million (USD 76.2 million) for the corresponding quarter last year, recording a YoY growth of 33.2%. EM delivered impressive performance in Q2 FY27, driven by robust secondary sales growth, continued market outperformance, portfolio expansion, and strong execution across regions. \uf0b7 Russia & CIS recorded healthy growth, led by the Dermatology portfolio, new product launches, and continued market share gains despite macroeconomic and currency headwinds. Amongst the Dermatology companies in Russia, Glenmark ranks 6th as of IQ DATA MAT SEP\u2019 2026. \uf0b7 LATAM delivered a strong Q2 FY27, with growth driven by key markets including Brazil, Mexico, and Colombia, supported by continued portfolio expansion and strategic investments in the Respiratory segment. RYALTRIS \u00ae was launched in Brazil during Q2 FY27, receiving encouraging feedback from physicians and distributors. \uf0b7 MEA business remained resilient amid geopolitical and supply chain challenges, with key countries outperforming their respective covered markets and continued success of RYALTRIS\u00ae, which strengthened its leadership position and\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"05-Nov-2026 17:04:32\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_05112026170258_SEInitmationresults.pdf\",\"disclosure_text\":\"Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B\/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com November 05, 2026 To, National Stock Exchange of India Limited, \u201cExchange Plaza\u201d, 5th Floor, Plot No. C\/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai \u2013 400 051 To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 64\/26-27 Our Reference No. 64\/26-27 Dear Sir\/ Madam, Sub: Outcome of Board Meeting for the quarter and half year ended September 30, 2026 - SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cListing Regulations\u201d), we wish to inform that the Board at its meeting held today, i.e. November 05, 2026 has approved the following: A. Financial Results 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026; and 2. Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. The meeting commenced at 1:15 p.m. and concluded at 4:15 p.m. You are requested to take the same on records. Thanking You. Yours faithfully, Rashmi Khandelwal Company Secretary & Compliance Officer ACS \u2013 28839 I II JJI IV V Vl VII VJJI IX X XI XII XJJI XIV xv XVI Glenmark Pharmaceuticals Limited Statement of Unaudited flnancial results for the quarter and half year ended 30 September 2026 (All amounts in million of Indian Rupees unless otherwis e stated) Particular\u2022 Quart.er ended Quarter eaded 30\/09\/2026 30\/06\/2026 ,Unaudltedl (Unaudited) Revenue from operations (a) Net sales 23,753.73 23,425.26 (b) Other operating income 1,004.47 924.67 Total revenu e from operations 24,758.20 24,349.93 Other incom e 1,081.93 1,154.11 Total income ( J + II } 25,840.13 25,504.04 Expenses {a) Cost of materials consumed 7,568.92 6,279.86 {b) Purch ases of stock-in-trade 1,236.40 1,414. 36 (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (538 .38) 491.60 (d) Employee benefits expense 4,497.66 4,540.81 (e) Financ e costs 309.34 232.45 {f) Depreciation, amortisation and impairment expense 629.97 623.17 (g) Other expenses 5,175.60 5,490.77 Total expenses (lV) 18,879.51 19,073.0 2 Profit\/ (loss) before exceptional items and tax ( III - IV ) 6,960.62 6,431.02 Exceptional items (gain)\/ loss (Refer note 5) 1,429.25 (2,230.00) Profit\/ (Joss) before tax (V - VI) 5,531.37 8,661.02 Tax expense [charge \/ (credit)I : Current tax 1,037.47 1,128.41 Deferred tax 144.96 176.24 Profit\/(loss) after tax for the period \/ year (VII - VIII) 4,348.94 7,356.37 Profit\/ (loss) for the period \/ year attributab le to: - Non-controlling interests - Owners of the parent 4,348.94 7,356.37 Other comprehensive income \/ {loss) A (i) Items that will not be reclassified to profit or loss (172 .58) 8.10 {ii) Income tax relating to items that will not be reclassified to profit or loss 20.71 (2.04) B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss Total other comprehensive incom e\/(loss) for the period\/ year (151.87) 6.06 Total comprehensive income for the period\/ year (IX+Xl) 4,197.07 7,362.43 Total comprehensive inco me attributable to: - Non-controlling interests - Owners of the parent 4,197.07 7,362.43 Paid up Equity Share Capital, Equity Shares of Re. 1 \/- each 282 .22 282.20 Other equity (other than revaluation reserve) Earnings per share (EPS) (not annualised except for the year ended 31 March) Basic (in Rupees ) 15.41 26.07 Diluted (in Rupees ) 15.41 26.06 G GlenmaQk A new way for a new world Standalone Quarter ended Half year ended Hall year ended Year eaded 30\/09\/2025 30\/09\/2026 30\/09\/2025 31\/03\/2026 (Ull.auditedJ (Ua.audltedJ ,Unaudited) (Audited) 12,195.32 47,178.99 33,984.28 79,342.23 3,191.28 1,929.14 5,351.60 5,058.76 15,386.60 49,108.13 39,335.88 84,400.99 2,857.56 2,236.04 3,550.91 7,720.23 18,24 4.16 51 ,344.17 42,886.79 92,121.22 6,678.20 13,848.78 13,450.60 27,755.75 913.13 2,650.76 1,906.38 4,087.95 (1,028.50) (46.78) (1,612.60) (1,054.15) 4,536.75 9,038.47 8,621.18 17,904 .10 233.96 541.79 388.54 787.45 589.34 1,253.14 1,165.73 2,358.89 6,067.00 10,666.37 11,468.71 24,933.36 17,989.88 37,952.53 35,388.54 76,773.35 254.28 13,391.64 7,498.25 15,347.87 9,317.94 (800.75) 12,550.26 18,008.58 (9,063.66) 14,192.39 (5,052.01) (2,660.71) (701.72) 2,165.88 (970.05) 321.20 (962.38) (652.72) (7,391.89) 11,705.31 (4,089.63) (2,007.99) (7,391.89) 11,705.31 (4,089.63) (2,007.99) (171.02) (164.48) (179.22) (159.85) 24.82 18.67 27.68 (9.71) (146.20) (145.81) (151.54) (169.56) (7,538.09) 11,559.50 (4,241.17) (2,177.55) (7,538.09) 11,559.50 (4,241.17) (2,177.55) 282.20 282.22 282.20 282.20 2,41,221.04 (26.19) 41.48 (14.49) (7.12) (26.19) 41.47 (14.49) (7.12) \\u002d\\u002d- \\\" Glenmark Pharmaceuticals Limited . . . \/;f:: ~ ('I ~ ~ ~ MAc~ =@ienm~H~B:D:-5aw:mt-\\\"Marg;\\\"-Alfdlmt 1 tE:m-}, Mrrmbru\u00b7400\u00b7099;\\u002d\\u002dInrlilf. . ~,-i - \u00b7 <\\\" ~ T: +91224018 9999 F: 91 22 4018 9986 CIN No.: L242~9M~1977PLC0199~2 W: www. *fua~~fil.tna.ffP } . ll; a.I g Registered Office: B\/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026 E: \u00a2<\\\"il_},~1anceoffi<y:. ,~l,n l~~I\\\\ ~ ,...__.\/ ~,\\u002d\\u002d \u00b7~~ er, Acco..::,-;;. ).9 * ,(:)',, I II III IV V VI VII VIII IX X XI XII XIII XIV xv XVI \\u002d\\u002d\\u002d\\u002d-~- ~ -\u00b7 Glenmark Pharmaceuticals Limited Statement of Unaudited financial results for the quarter and half year ended 30 September 2026 (All amounts in million of Indian Rupees, unless otherwise stated) Particulars Quarter ended Quarter esaded 30\/09\/2026 30\/06\/2026 (Vo.audited) (Unaudited I Revenue from operations (a) Net sales 41,570.91 39,317.30 (b) Other operating income 902.37 867.53 Total revenue from operations 42,473.28 40,184.83 Other income 25.41 657.64 Total income { I + II ) 42, 498.69 40 ,842.47 Expenses (a) Cost of materials consumed 8,378.80 6,010.66 (b) Purchases of stock-in- trade 5,298.39 6,607.53 (c) Changes in inventorie s of finished goods, work-in-progress and stoc k-in-trade (621.85} (160 .20) (d) Employee benefits expens e 10,276.44 9,346.95 (e) Finance costs 637.67 539.97 (f} Depreciation, amortisation and impairment expense 1,804.16 1,731.74 (g) Other expenses 10,503 .45 10,331.93 Total expenses (IV) 36,277.06 34,408.58 Profit\/ (loss) before exceptional items and tax ( III - N ) 6,221.63 6,433.89 Exceptional items (gain)\/ loss (Refer note 5) 2,838.75 Profit\/(loss} before tax (V - VI) 3,382 .88 6,433.89 Tax expense (charge \/ (credi t)I : Current tax 1,279.93 2,108.17 Deferred tax (535.35) (502.56} Profit\/(loss} after tax for the period \/ year ( VII - VIII} 2,638.30 4,828.28 Profit \/ (loss} for the period \/ year attrib utable to: - Non-controlling interests 0.47 (0.96) - Owners of the parent 2,637.83 4,829 .24 Other comprehensive income \/ (loss) A (i) Items that will not be reclassifie d to profit or los s (182.84) 7.43 (ii) Income tax relating to items that will not be reclassified to profit or loss 22.17 (2.12) B (i) Items that will be reclass ~fied to profit or loss (73.53) 450 . 17 (ii) Income tax relating to items that will be reclassified to profit or loss (89.62} (51.00} Total other comprehensive incom e\/ (loss) for the period\/ year (323.82) 404.48 Total comprehens ive income for the period\/ year (IX+ XI} 2,314.48 5,232.76 Total comprehens ive income attributable to: - Non-controlling interests 0.43 (0.90) - Owners of the parent 2,314.05 5,233.66 Paid up Equity Share Capital, Equity Shares of Re. I\/- each 282.22 282.20 Other equity {other than revaluation reserve) Earnings per share (EPS) (not annualise d except for the year ended 31 March) Basic (in Rupees ) 9.35 17.11 Dilu ted (in Rupees) 9.34 17.11 \u00a3cy}.'.,JJn , ':-~ ,_f.\\\"6:-,;\\u002d\\u002d ~tefh\u00b5 ark P_!i~_11:1aceuticals Limited -\u00b7\u00b7\u00b7 _ -~ - \u00b7\u00b7 G c;lenma~k A new way for a new world Consolidated Quarter eu.ded Half year ended Half year eaded Year ended 30\/09\/2025 30\/09\/2026 30\/09\/2025 31\/03\/2026 (Unaudited) (Unauditedl (Unaudited) (Audited. I 60 ,037 .94 80,888 .2 1 90,631.27 1,67,114.03 430.76 1,769.90 2,481.83 2,711.08 60,468.70 82,658.11 93,113.10 1,69,825.11 2,006.29 683.05 2,270.71 4,606.19 62,474.99 83,341.16 95,383.81 1,74 ,431.3 0 7,225.00 14,389.46 14,549.68 29, 614.59 6,204.46 11,905.92 12,017.87 23,9 66.43 (784.41) (782.05) (3,766.74) (6,106.39) 10,862.59 19,623. 39 18,490.13 35,778.53 664.63 1,177.64 1,246.89 2,087.25 1,412.00 3 ,535.90 2,711.26 5,734.81 13,365.55 20,835.38 22,421.45 40,847.78 38,949.82 70,685.64 67,670.54 1,31,923.00 23,525.17 12,655.52 27,713.27 42,508.30 13,851.1 6 2,838.75 17,083.48 22,660.84 9,674.01 9,816.77 10,629.79 19,847.46 4,600.25 3,388.10 5,693.36 6,764.86 (1,030.56} (1,037.91) (1,637.62} (536.92} 6,104 .32 7,466.58 6,574.05 13,619.52 0.79 (0.49) 1.81 I.OJ 6,103.53 7,467.07 6,572.24 13,618.5 1 (182.86) (175.41} (174.22) (93.85) 25.32 20.05 23.49 (23.59 ) 1,4 18.54 376.64 2,436 . 14 4,831.97 (216.24} (140.62} (227.53} (570.93} 1,044.76 80.66 2,057.88 4,143.60 7,149.08 7,547.24 8,631.93 17,763.12 0.68 (0.47) 1.55 0.55 7,148.40 7,547.71 8,630.38 17,762.56 282.20 282.22 282.20 282.20 1,04,838.8 9 21.63 26.46 23.29 48.26 21.62 26.45 23.28 48.24 7 r~~ -.,\\u002d\\u002d ~~Gl~mfia rk House, B.D. Sawant Marg, Anoheri (East), Mumoai 400 099, India. \\\\ n MUMo\/iJT: +~)]~2 4018 9999 F: 91224018 9986 CIN No.: L242~9M~1977PLC0199~2 W: www.glenm~kpharma.com '\\\\ ~ \\\\ ~~11f ted Office: B\/2, Mahalaxmi Chambers, 22, Bhulabha.t Desai Road, Mumbai 400 026 E: comphanceofficer@glenm ' 'P;;. '\\u002d\\u002d _,\/ -.;J\\\" ,\u00a2 \u00b7 - - - ~ 1\/.<,, ,, D ' (\u00b7'\\\"'i:J'\/,'' .,.. {\\u002d\\u002d-. <V \u00b7~ _,., ,,,,.. Glenmark Phannaceutlcals Limited Balance sheet (All amowits in million of Indian Rupees unless otherwise stated) Particulars ASSETS ft' on current aasets Property, plant and equipmen t Capital work -in-progress Right-of-use asset Goodwill Other intangible assets Intangible assets under developm ent Financ ial assets (i) Investment s (ii) Loans (iii) Other finan cial assets Deferred tax assets (net) Income tax assets (net) Other non-curr ent assets Total non- current assets Current asset. Invento ries Financial assets {i) Trade receiva bles (ii) Cash and cash equival ents (iii) Bank baJance other than cash and cash equi valents (iv) Other finan cial asse ts Other current asset s Total current assets Total assets EQUITY AND LIABILITIES Equity Equity share capital Other equity Equity attribut able to owner s' of parent Non-controlling interests Liabilities Non-current liabilities Financial liabili ties (i) Borrowin gs (ii) Lease liabiliti es (iii) Other finan cial liabilitie s (iv) Provision Deferred tax liabilities (net) Other non - current liabilities Total non-current liabilities Current liabilities Financial liab ilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables - Total outstand ing dues of micro enterpris es and small enterprises - Total outstanding dues of other than micro enterprises and small enterpris es (iv) Other finan cial liabiliti es Other current liabilities Provisions Current tax liabilities lnetl Total current liabilities Total liabilities Total eauit v and liabilities ,(.l.~c'.\\\\Ai'JD\/o. \u2022 ~\u00b75,,,,....\\u002d\\u002d. <? i,:'I' \\\\~ sf ,~ i't ( Al f\\\" ,;;.\\\\ . r\u00b7:: ~,,,\\\\ \/~r:: <,-,, '-..._ _., >yo\u00b7 .. \u2022 J \u00b7rt:o ACC~ ,'s Novembe, 2026 Glenmm Pharmaceuticals Limited G qlenma~k A new way for a new world Standalone Conoolldated As at 30\/09\/2026 (Unudited l 16,992.62 1,106.99 902.8 9 1,695. 76 1,255. 82 1,5 2, 022.07 59, 045.01 373.63 791.43 448.65 2,34,634.87 14,978.11 34,242.3 2 1,762.73 5.81 5,804.90 9 971.66 66,76S.53 301 ,400.40 282.22 2 52 .107.8 9 2,52,39 0.11 664.67 6,064.05 258.31 242. 13 8 79 1.60 16,020.76 . 3 19.11 238. 07 26,250.78 1,247 .26 572.61 2,72 5.57 1,636.13 32,989.53 49,010.29 301 ,400.40 As at Asat As at 31\/03\/2026 30\/09\/2026 31\/03\/2026 IAudited l Rlnaudited l IAudlted l 17,476.58 33,067.41 33,441.13 673.62 5,994.71 4,27 8. 73 1,009.89 5,116.88 5,454.56 847.0 3 828.64 1,792.53 19,627.52 19,421.08 919.59 5,194.44 4 ,812.56 1,52,022 .10 423.53 423.56 55,820 .74 367.41 693. 84 675.26 60.40 13,889 .43 12 ,466. 12 2 ,016.51 1,331.70 2,5 14.0 5 1,741.45 676 .33 1,968.70 2,33,900.82 86,862.82 86,284 .39 12,880.64 37,461.92 34,307.76 33,055.85 54,937.42 49,633.54 2,918.31 12,899.29 11,747.09 13.6 2 7.72 15.48 4,256.34 2,1 27.95 2,247.26 7,826.20 19 705.49 14,843.25 60,950.96 1,27,139.79 1, 12,794 .37 2 94 851 .78 2 ,14,002.61 199 078 .76 282.20 282 .22 282.20 2 41.221.04 1.1 1 842 .14 1.04 .838.89 2,4 1,503.24 1, 12,124. 36 1,05 ,12 1.09 (3.63) (3.16) 747.42 4,363.9 8 4,863.07 5,353.11 9,790 .00 8,193.68 1,76 6.14 258.31 1,766.1 4 252.72 12.3 1 8 791.60 12 .148 .74 15 361.37 16,658.27 26,813.75 30,196.157 8,665.40 322.71 1,045.3 2 1,072.20 2 13.2 3 281.38 230.63 27,247.19 39,830.02 37,208 .09 4 ,215.90 3,58 1.62 4,985 .96 1,028.68 8,369.91 8,621.20 3,662 .56 10,580.2 3 10,70 0 .89 2 714 .25 945 .29 36,690.27 75,068.13 63,764.26 153,348.54 1,01,881.88 93,960 .83 2 ,94 851 .78 2,14 ,002.61 199 078.76 For and on behalf of the Board of Directors Glenn Saldanha Chairman & Managing Director Glenmarl.<House, BJJ\\\":\\\"Sawant'Marg, Aiialiert(East) ~Jvfumbai\u00b7400-099;-1n~!ia. T: +91224018 9999 F: 91224018 9986 CIN No.: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered Office: B\/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026 E: complianceoflicer@glenmarkpharma.com Glenmark Pharmaceuticals Limited Statement of cash nows for the half year ended 30 September 2026 (All amounts in million of Indian Rupees, unless otherwise stated) Particulars A. Cash flow from operating activities Profit before tax Adjustments for: Depreciation, amortisation and impairment expense Finance costs Interest income Dividend income Loss\/ (Profit) on sale of Property, plant and equipments Net gain on sale of current investment carried at FVTPL Employee share based compensation expense Fair valuation of Investm ent Provision for sales returns Exceptional items (gain)\/ loss Unrealised foreign exchange (gain)\/loss Operating profit before working capital changes Adjustments for changes in working capital : - (Increase)\/ Decrease in trade receivables - (Increase) \/ Decrease in other receivabl es - (Increase)\/ Decrease in inventories -Increase\/ (Decrease) in trade and other payables Net changes in operating assets and liabilities - Income taxes paid (net of refunds) Net cash generated from \/ (used in l operating activities B. Cash flow from investing activities Purchase of Property,plant and equipment and Intangible assets (including Capital work in progress , capital advances and capital creditors) Proceeds from sale of Property,plant and equipment, Intangible assets Investments in subsidiari es Investments in associates Proceed from Subsidiary company against business sale Loans (given to)\/ repaid by subsidiaries (net) Investments in bank deposits and margin money (net) Proceed from Mutual fund (net) Interest received Dividend received Net cash generated from\/ (used in) investing activities C. Cash flow from f'mancing activities Proceed from issue of equity shares Proceeds from\/(repayment of) short-term borrowings ( net) Inter est paid Dividend paid Principal payment of lease liabilities Interest paid on lease liabilities Net cash generated from \/ (used in) financing activities Net (decrease) \/ increase in cash and cash equivalents Opening balance of cash and cash equivalents Exchange difference on cash and cash equivalent Closing balance of cash and cash equivalents -\u00b7'c_~ \u00b7 enmar armaceu c s Dl1 e G Glenma~k A new way for a new world Standalone Half year ended Half year ended 30\/09\/2026 30\/09\/2025 naudited (Unaudited) 14,192 .39 (5,052.01) 1,253 . 14 1,165 .73 541.79 388.54 (1,226 .52) (898.36) (0.08) (0.03) 3.22 2.92 (0.16) 18.62 0.00 0.03 (0.16) 50.00 (800.75) 12,550 .26 (1,015.05) (1,380.77) 13,016.79 6,775.96 (1,377.91) (8,381.70) (1,059 .21) (3,746.59) (2,097.48) (2,400.27) (7,789.38) 5,921.84 (12,323.98) (8,606.72) 695 .33 (283 .01) 1,388.14 (2,113.77) (1,244.64) (1,414 .63) 11.60 8.82 (0.50) (2.40) 875.00 (1 ,137.92) 5,760 .95 (20.97) 0.46 0.16 367.06 1,238.28 0.08 0.03 (1,149.79) 5,591.17 14.31 7.59 (3,412.46) (493.63) (326.39) (713 .37) (0.46) (150.47) (141.06) (50.79) (64.20) (1,393.95) (3,936.98) (1,155.60) (459.58) 2,918 .31 1,314.51 0.02 (0.22) 1,762.73 854.71 ;}-Y, P\\\\9J~ 2 4018 9999 F: 91224018 9986 CIN No.: L24299MH1977PLC019982 W: www.glenmarkpharma.com G ~~~IZ'Flouse, B:D\u00b7: Sawant Marg, Anci.heri(EiiiJ;Mum \u00b7t>a1~4\\\"0O-o99,-inaia-.\\u002d\\u002d- \u2022\u2022 I ,. Regi\\\\f{r.\u00b7 \\\\d Office: B\/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmacl , MBA! 'jt,:( ~ . lo,} ~ . .\/.s;.1\/ , ,?, ,.._ _ _, ~-t;Y ~D t.r:f'.o'S~_#\u00b7 Glenmark Pharmaceuticals Limited Consolidated statement of cash flows for the half year ended 30 September 2026 (All amounts in million of Indian Rupees, unless otherwise stated) Particulars (A) Cash flow from operating activities Profit before tax from operations Adjustments for: Depreciation, amortisation and impairment expense Finance costs Interest income Dividend income (Profit)\/loss on sale of property, plant and equipments Net gain on sale of current investment carried at FVTPL Fair valuation of Investment Provision for doubtful debts \/ expected credit losses Employee share based compensation expense Provision for sales returns Exceptional items (gain)\/ loss Unrealised foreign exchang e (gain)\/loss Operating profit before working capital changes Adjustments for changes in working capital : - (Increase)\/ Decrease in trade receivables - (Increase) \/ Decrease in inventories - (Increase)\/ Decrease in other assets - Incr\"}],\"recent_news\":[{\"summary\":\"Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"05-Nov-2026 17:04:32\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_05112026170258_SEInitmationresults.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated October 06, 2026, titled \\\"Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 08:38:46\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_06102026083500_SEIntimation_06102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 23, 2026, titled \\\"Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa facility with VAI classification\\\".\",\"category\":\"Press Release\",\"date\":\"23-Sep-2026 08:41:06\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_23092026083959_SEPressRelease23092026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 11, 2026, titled \\\"Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS\u00ae Launch in Brazil \\\".\",\"category\":\"Press Release\",\"date\":\"11-Sep-2026 08:50:55\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/GLENMARK_11092026085036_Press_Release_11092026_Signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":46.65,\"public_pct\":53.35,\"fii_pct\":21.51,\"dii_pct\":17.64,\"mf_pct\":15.61,\"institutional_pct\":39.15,\"noninst_pct\":14.17,\"mf_scheme_count\":38,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC MUTUAL FUND - HDFC MANUFACTURING FUND\",\"shares\":16953594,\"pct\":6.01},{\"name\":\"INVESCO INDIA PHARMA AND HEALTHCARE FUND\",\"shares\":5572933,\"pct\":1.97},{\"name\":\"BANDHAN LARGE CAP FUND\",\"shares\":3617749,\"pct\":1.28}],\"period\":\"30-SEP-2026\",\"submission_date\":\"19-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741223_19102026122950_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":46.65,\"previous_fii_pct\":20.89,\"previous_dii_pct\":18.6,\"previous_mf_pct\":16.76,\"previous_institutional_pct\":39.49,\"previous_mf_scheme_count\":37,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Buy\",\"target\":\"2570\",\"view_summary\":\"Stocks To Buy Today: Coforge, Timex To Glenmark Pharma \u2014 Five Stock Picks By Motilal Oswal's Chandan Taparia NDTV Profit\",\"headline\":\"Stocks To Buy Today: Coforge, Timex To Glenmark Pharma \u2014 Five Stock Picks By Motilal Oswal's Chandan Taparia\",\"published\":\"2026-08-31T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"ICICI Securities\",\"rating\":\"Hold\",\"target\":\"2100\",\"view_summary\":\"Hold Glenmark Pharmaceuticals; target of Rs 2100: ICICI Securities Moneycontrol.com\",\"headline\":\"Hold Glenmark Pharmaceuticals; target of Rs 2100: ICICI Securities\",\"published\":\"2026-08-04T07:00:00+00:00\",\"source\":\"Moneycontrol.com\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals moved 8.06% intraday and closed 4.36% higher at \u20b92,590.00. See the catalyst, volume context and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":11152,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Glenmark Pharmaceuticals Share Price Jumps 8.06% Intraday, Closes 4.36% Higher | 6 November 2026","_witty_meta_description":"Glenmark Pharmaceuticals moved 8.06% intraday and closed 4.36% higher at \u20b92,590.00. See the catalyst, volume context and what to watch next.","_witty_primary_phrase":"Glenmark Pharmaceuticals share price today","_witty_reason_label":"Post-earnings follow-through and sector outperformance","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[37],"class_list":["post-11153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-glenmark"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=11153"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11153\/revisions"}],"predecessor-version":[{"id":11154,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11153\/revisions\/11154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/11152"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=11153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=11153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=11153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}